Germantown, MD, United States of America

ChangHung Chen

This inventor holds 9 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Wellstat Immunotherapeutics, LLC, Precigen, Inc., Biopharma Credit Plc, as Collateral Agent. Active years: 2016-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: ChangHung Chen. Retrieved from https://idiyas.com/inventor/changhung-chen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 2)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 5)

Average Co-Inventor Count = 5.3

ph-index = 2

Forward Citations = 9(Granted Patents)

Location History:

Germantown, MD (US) (2016 - 2021)
Blacksburg, VA (US) (2022)

Company Filing History:

5 out of 6

Wellstat Immunotherapeutics, LLC

Biopharma Credit Plc, as Collateral Agent

patents

Years Active: 2016-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760083 - CHIMERIC RECEPTOR THERAPY (2026-10-13),

2. 12703747 - FUSION CONSTRUCTS AND METHODS OF USING THEREOF (2026-08-11),

3. 12275772 - ROR-1 specific chimeric antigen receptors and uses thereof (2025-04-14),

4. 11535669 - Fusion constructs and methods of using thereof (2022-12-27),

5. 11001822 - Complement factor B analogs and their uses (2021-05-11),

6. 10689637 - Complement factor B analogs and their uses (2020-06-23),

7. 10415026 - Complement factor B analogs and their uses (2019-09-17),

8. 9533028 - Complement factor B analogs and their uses (2017-01-03),

9. 9228003 - Complement factor B analogs and their uses (2016-01-05),

Title: ChangHung Chen: Innovator in Complement Factor Research

Introduction

ChangHung Chen, an accomplished inventor based in Germantown, MD, is known for his significant contributions to the field of immunotherapy. With a total of five patents to his name, Chen's work primarily focuses on polypeptides and their applications in modulating complement pathways, which are crucial for understanding and treating various diseases.

Latest Patents

His latest patents revolve around complement factor B analogs, aiming to provide novel polypeptides that comprise these analogs. These patents detail various mutations and related methods, nucleic acids, and vectors that can be utilized to modulate complement pathways or for the scientific study and treatment of diseases connected to these pathways. This innovative research has the potential to enhance therapeutic options in immunology.

Career Highlights

ChangHung Chen's professional journey includes a notable position at Wellstat Immunotherapeutics, LLC, where he has been able to further his research and development in the therapeutic applications of complement factor B. His expertise and dedication to innovation have positioned him as a crucial player in the field of immunotherapy.

Collaborations

Throughout his career, Chen has collaborated with distinguished colleagues such as Michael Kaleko and Beibei Li. These partnerships have fostered a dynamic research environment that promotes the exploration of new scientific frontiers in immunotherapy.

Conclusion

ChangHung Chen's innovations in complement factor research not only underscore his status as a prominent inventor but also highlight the importance of collaboration in advancing healthcare solutions. With his continued contributions, the field of immunotherapy may see new breakthroughs that significantly impact disease treatment and management.

Profile summary based on public USPTO records.